4.8 Article

DNA-based platform for efficient and precisely targeted bioorthogonal catalysis in living systems

Journal

NATURE COMMUNICATIONS
Volume 13, Issue 1, Pages -

Publisher

NATURE PORTFOLIO
DOI: 10.1038/s41467-022-29167-x

Keywords

-

Funding

  1. National Key R&D Program of China [2021YFF1200700, 2019YFA0709202]
  2. National Nature Science Foundation of China [21871249, 21820102009, 91856205, 21977091]
  3. Jilin Province Science and Technology Development Plan Project [20200201241JC]
  4. Key Program of Frontier of Sciences [CAS QYZDJ-SSW-SLH052]

Ask authors/readers for more resources

This study reports on a DNA-based biocompatible, highly efficient, and precisely targeted copper nanocatalyst, which exhibits excellent catalytic activity and achieves efficient prodrug activation and antitumor effects in cancer cells.
Copper-click reaction has been used for a wide range of bio-conjugations but does suffer from toxicity issues. Here, the authors report on the growth of copper nanoparticles on DNA with linked aptamer targeting and demonstrate high catalytic effect and improved application due to targeting and biocompatibility. As one of the typical bioorthogonal reactions, copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) reaction holds great potential in organic synthesis, bioconjugation, and surface functionalization. However, the toxicity of Cu(I), inefficient catalytic activity, and the lack of cell specific targeting of the existing catalysts hampered their practical applications in living systems. Herein, we design and construct a DNA-based platform as a biocompatible, highly efficient, and precisely targeted bioorthogonal nanocatalyst. The nanocatalyst presents excellent catalytic efficiency in vitro, which is one order of magnitude higher than the commonly used catalyst CuSO4/sodium ascorbate. The theoretical calculation further supports the contribution of DNA structure and its interaction with substrates to the superior catalytic activity. More importantly, the system can achieve efficient prodrug activation in cancer cells through cell type-specific recognition and produce a 40-fold enhancement of transformation compared to the non-targeting nanocatalyst, resulting in enhanced antitumor efficacy and reduced adverse effects. In vivo tumor therapy demonstrates the safety and efficacy of the system in mammals.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available